v3.26.1
Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($)
$ in Thousands
Lucid Diagnostics 2018 Equity Plan [Member]
Preferred Stock [Member]
Lucid Diagnostics 2018 Equity Plan [Member]
Common Stock [Member]
Lucid Diagnostics 2018 Equity Plan [Member]
Additional Paid-in Capital [Member]
Lucid Diagnostics 2018 Equity Plan [Member]
Retained Earnings [Member]
Lucid Diagnostics 2018 Equity Plan [Member]
PAVmed 2014 Equity Plan [Member]
Preferred Stock [Member]
PAVmed 2014 Equity Plan [Member]
Common Stock [Member]
PAVmed 2014 Equity Plan [Member]
Additional Paid-in Capital [Member]
PAVmed 2014 Equity Plan [Member]
Retained Earnings [Member]
PAVmed 2014 Equity Plan [Member]
Registered Direct Offering [Member]
Preferred Stock [Member]
Registered Direct Offering [Member]
Common Stock [Member]
Registered Direct Offering [Member]
Additional Paid-in Capital [Member]
Registered Direct Offering [Member]
Retained Earnings [Member]
Registered Direct Offering [Member]
At-the-market Offering [Member]
Preferred Stock [Member]
At-the-market Offering [Member]
Common Stock [Member]
At-the-market Offering [Member]
Additional Paid-in Capital [Member]
At-the-market Offering [Member]
Retained Earnings [Member]
At-the-market Offering [Member]
Conversion of Preferred Stock into Common Stock [Member]
Preferred Stock [Member]
Conversion of Preferred Stock into Common Stock [Member]
Common Stock [Member]
Conversion of Preferred Stock into Common Stock [Member]
Additional Paid-in Capital [Member]
Conversion of Preferred Stock into Common Stock [Member]
Retained Earnings [Member]
Conversion of Preferred Stock into Common Stock [Member]
Abeyance Shares [Member]
Preferred Stock [Member]
Abeyance Shares [Member]
Common Stock [Member]
Abeyance Shares [Member]
Additional Paid-in Capital [Member]
Abeyance Shares [Member]
Retained Earnings [Member]
Abeyance Shares [Member]
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance (in shares) at Dec. 31, 2024                                                             54,419 63,071,950      
Balance at Dec. 31, 2024                                                             $ 54,419 $ 63 $ 154,675 $ (203,766) $ 5,391
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan (in shares)                                                             0 1,893      
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan                                                             $ 0 $ 0 3 0 $ 3
Stock-based compensation $ 0 $ 0 $ 949 $ 0 $ 949 $ 0 $ 0 $ 81 $ 0 $ 81                                                  
Stock issuance (in shares)                     0 13,939,331                                              
Stock issuance                     $ 0 $ 14 $ 14,920 $ 0 $ 14,934                                        
Purchase - Employee Stock Purchase Plan (in shares)                                                             0 203,051     203,051
Purchase - Employee Stock Purchase Plan                                                             $ 0 $ 0 141 0 $ 141
Issuance - Interest payment paid in stock (in shares)                                                             0 40,767      
Issuance - Interest payment paid in stock                                                             $ 0 $ 0 32 0 32
Issuance - Dividend on Series B Preferred Stock (in shares)                                                             0 7,117,463      
Issuance - Dividend on Series B Preferred Stock                                                             $ 0 $ 7 9,103   0
Issuance - Dividend on Series B Preferred Stock                                                                   (9,110)  
Net loss                                                             $ 0 $ 0 0 (26,908) (26,908)
Balance (in shares) at Mar. 31, 2025                                                             54,419 84,374,455      
Balance at Mar. 31, 2025                                                             $ 54,419 $ 84 179,904 (239,784) (5,377)
Issuance - Dividend on Series B Preferred Stock                                                                   (9,110)  
Balance (in shares) at Dec. 31, 2025                                                             54,274 131,098,762      
Balance at Dec. 31, 2025                                                             $ 54,274 $ 131 230,866 (274,335) $ 10,936
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan (in shares)                                                             0 15,157     15,157
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan                                                             $ 0 $ 0 20 0 $ 20
Stock-based compensation $ 0 $ 0 $ 1,402 $ 0 $ 1,402 $ 0 $ 0 $ 9 $ 0 $ 9                                                  
Vest - restricted stock awards (in shares)                                                             0 20,622      
Vest - restricted stock awards                                                             $ 0 $ 0 0 0 $ 0
Stock issuance (in shares)                               0 4,161,747     4,161,747           0 2,363,929                
Stock issuance                               $ 0 $ 4 $ 5,270 $ 0 $ 5,274           $ 0 $ 3   $ 0 $ 0          
Purchase - Employee Stock Purchase Plan (in shares)                                                             0 242,284     242,284
Purchase - Employee Stock Purchase Plan                                                             $ 0 $ 0 210 0 $ 210
Issuance - Interest payment paid in stock (in shares)                                                             0 69,382      
Issuance - Interest payment paid in stock                                                             $ 0 $ 0 75 0 75
Issuance - Dividend on Series B Preferred Stock (in shares)                                                             0 7,094,159      
Issuance - Dividend on Series B Preferred Stock                                                             $ 0 $ 7 9,712   0
Issuance - Dividend on Series B Preferred Stock                                                                   (9,719)  
Conversions - Series B Preferred Stock (13,294,267 shares held in abeyance) (in shares)                                         (44,140)                            
Conversions - Series B Preferred Stock (13,294,267 shares held in abeyance)                                         $ (44,140)                            
Conversions - Series B Preferred Stock (13,294,267 shares held in abeyance) (in shares)                                           19,812,596                          
Conversions - Series B Preferred Stock (13,294,267 shares held in abeyance)                                           $ 20 $ 44,120 $ 0 $ 0                    
Stock issuance                                                       $ (3)              
Tax withholdings on equity based compensation                                                             0 0 (17) 0 (17)
Net loss                                                             $ 0 $ 0 0 (13,909) (13,909)
Balance (in shares) at Mar. 31, 2026                                                             10,134 164,878,638      
Balance at Mar. 31, 2026                                                             $ 10,134 $ 165 $ 291,664 (297,963) $ 4,000
Issuance - Dividend on Series B Preferred Stock                                                                   $ (9,719)